Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1–42 levels
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Matrix metalloproteinases (MMPs), a family of extracellular soluble or membrane bound endopeptidases, are implicated in many physiological and pathophysiological functions—based on their capability to cleave all protein components of the extracellular matrix. Recent studies have implicated several forms of MMPs in chronic neurodegenerative diseases like Alzheimer’s disease (AD), vascular dementia (VD), and Parkinson’s disease (PD). The aim of the present study was to analyse eight MMPs (MMP-1, -2, -3, -7, -8, -9, -10, -13) in the human cerebrospinal fluid (CSF) and to correlate with the well established biomarkers beta-amyloid1–42 (Aβ), total-tau and phospho-tau-181. Our data show a significant decrease of MMP-2 and MMP-3 levels in the CSF in samples with significantly reduced Aβ levels. It is concluded that MMP-2 and MMP-3 are directly linked to Aβ in the brain and a dysfunction may influence the processing of Aβ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Metalloproteinases: Mediators of Pathology and Regeneration in the CNS
Yong, V. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1807 · Cited by 582 · cited 3×
“Because of the high potential of tissue destruction MMPs are highly controlled at the gene expression, pro-enzyme activity and secretion to prevent tissue damage [26].”
BackgroundInfluentialBackstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331 · cited 3×
“An accumulation of MMPs in AD brains in the proximity of extracellular amyloid plaques has been shown [2] and a reduction of MMPs may contribute to Aβ accumulation and consequently to AD development.”
BackgroundWhite, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284
Cited by
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
“These results suggest that behavioral stress aggravates AD pathology via generation of metabolic oxidative stress and MMP-2 down-regulation (Lee et al. 2009; Mlekusch and Humpel 2009; Nalivaeva et al. 2008).”
BackgroundBrkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
“In contrast, Mlekusch andHumpel observed downregulation of MMP-3 and MMP-2 in CSF of AD patients, but it should be noted that these patients had lower Aβ levels [175].”
BackgroundBjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180
“Reduced CSF levels of MMP − 2 MMP − 3 have been found in AD patients with significantly reduced A 1-42 levels, possibly reflect-ing formation [30].”
Matrix metalloproteinases in Alzheimer’s disease and concurrent cerebral microbleeds.
Duits, F. H., Hernandez-Guillamon, M., Montaner, J., Goos, J. D. C., Montañola, A., Wattjes, M. P., Barkhof, F., Scheltens, P., Teunissen, C. E., & van der Flier, W. M. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143186 · Cited by 92
ECM in brain aging and dementia
Morawski, M., Filippov, M., Tzinia, A., Tsilibary, E., & Vargova, L. (2014) · Progress in Brain Research · doi:10.1016/b978-0-444-63486-3.00010-4 · Cited by 84
Metadata
- Authors
- Mlekusch, R., & Humpel, C.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 466
- Issue
- 3
- Pages
- 135-138
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2102282149
- Cited by
- 49
- References
- 4
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1–42 levels. https://app.cochat.ai/papers/10.1016/j.neulet.2009.09.043
- The paper
- Mlekusch, R., & Humpel, C. (2009). Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1–42 levels. Neuroscience Letters. https://doi.org/10.1016/j.neulet.2009.09.043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.